<DOC>
	<DOCNO>NCT02925702</DOCNO>
	<brief_summary>Prospective Multi-centre Study Prognostic Factors Castration Resistant PROState Cancer Treated With Radium 223</brief_summary>
	<brief_title>PRORADIUM : Prospective Multi-centre Study Prognostic Factors CRPC Treated With Radium-223</brief_title>
	<detailed_description>Observational study analyze prognostic factor castration resistant prostate cancer patient .</detailed_description>
	<mesh_term>Prostatic Neoplasms</mesh_term>
	<mesh_term>Radium Ra 223 dichloride</mesh_term>
	<criteria>1 . Provision informed consent . 2 . Eighteen year age old . 3 . General health status acceptable compatible active treatment : ECOG â‰¤02 . 4 . Histological confirmation prostate cancer diagnosis . 5 . Prior resistance biochemical castration LHRH agonist ( surgical castration bilateral orchiectomy ) progression antiandrogen drug ( e.g . bicalutamide , nilutamide cyproterone acetate ) . 6 . Biochemical progression upon prior treatment agreement PSAWG2 criterion , confirm second PSA test . 7 . Castrate level testosterone peripheral blood : testosterone &lt; 0.5 ng/ml . 8 . Candidates standard treatment Radium223 ( 55 kBq/kg 28 day 6 cycle ) 9 . Availability anatomopathological tumour material ( e.g . paraffin block prostatectomy initial biopsy metastasis ) . 10 . Acceptable hematological , hepatic renal function without contraindication administration abiraterone agreement respective summary product characteristic . 1 . Previous cancer diagnosis , except patient localize malignant tumour five year cancerfree , well subject history skin cancer ( nonmelanoma type ) excise situ carcinoma . 2 . Medical history , psychiatric character , , accord judgement investigator , might interfere subject 's granting informed consent safe execution procedure require study .</criteria>
	<gender>Male</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2017</verification_date>
</DOC>